banner
Melanoma Surgery »  Faculty »  Medical Oncology »  Alain Algazi, M.D.

Alain Algazi, M.D.

Assistant Clinical Professor of Medicine
Department of Medicine
Division of Hematology/Oncology

Contact Information

Academic Office
Fax: 415-476-0624
alain.algazi@ucsf.edu

Appointments

1600 Divisadero St., Fourth Floor
San Francisco, CA 94115
Phone: (415) 353-9900
Fax: (415) 885-3802
Open Popup
  • University of California, San Diego  1985-1987
  • University of California, Davis A. B. with honors 1987-1989 Psychology
  • UC Davis, UC Berkeley, UCLA  1991-1999 Post-Baccalaureate Courses
  • University of California, Los Angeles M. D. 1999-2004 Medicine
  • University of California, Los Angeles Internship 2004-2005 Internal Medicine
  • University of California, Los Angeles Residency 2005-2007 Internal Medicine
  • University of California, San Francisco Fellowship 2007-2010 Hematology/Oncology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology Oncology
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Melanoma Center
  • Basal Cell Carcinoma
  • Kaposi's sarcoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Skin adnexal tumors
  • Skin Cancer in Immunosuppressed Patients
  • Skin sarcomas
  • Squamous Cell Carcinoma
  • Molecular Aberrations in melanoma
  • Phase I Investigational Agents
  • Targeted Therapy in Melanoma

Alain Algazi, M.D., is an Assistant Clinical Professor of Medicine in the Department of Medicine,
Division of Hematology/Oncology and medical oncologist. A skin cancer specialist, he is based at the Melanoma Center on the campus of the UCSF Helen Diller Family Comprehensive Cancer Center,

Dr. Algazi treats patients with high-risk and advanced melanoma as well as those with extensive squamous cell and Merkel cell carcinoma of the skin.

Dr. Algazi earned a medical degree at the UCLA School of Medicine and completed an internal medicine residency at UCLA Medical Center. He completed a fellowship in hematology and oncology at UCSF. He is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

In his research, Algazi conducts clinical trials using personalized medicine for patients with advanced melanoma. These trials give patients access to new medications, including drugs called BRAF inhibitors that cause melanoma tumors to shrink in a majority of patients treated. He is looking for ways to improve the effectiveness of these medications.

  1. Algazi AP, Kadoch C, Rubenstein JL (2009). Biology and treatment of primary central nervous system lymphoma.  Neurotherapeutics. 2009 Jul;6(3):587-97.
  2. Algazi AP, Soon CW, and Daud, AI (2010). Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Management and Research.  In press.
  3. Soon CW, Algazi AP, Cha EN, and Daud AI (2010).  New horizons in melanoma treatment: Targeting molecular pathways.  The Oschner Journal.  2010. 10(2): 93-98.
  4. Algazi AP, Weber JS, Andrews S, Urbas P, Arimura E, Hwang J, Sondak VK, Bastian B, Daud, A.  A phase I/II trial of DTIC and dasatinib in metastatic melanoma.  Journal of Clinical Oncology. 2010. 28(15s):619s. Abstract 8532.
  5. Daud AI, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, DeConti RC.  Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.  British Journal of Cancer.  In press.

X